ANKRD46

ANKRD46 is consistently identified as a 3' UTR-targeted effector gene regulated by oncogenic and tissue-context miRNAs, rather than through any defined intrinsic biochemical activity (PMID:21219636, PMID:25542822). It is a direct target of miR-21, which binds its 3' UTR and represses its expression in breast cancer cells, such that miR-21 knockdown increases ANKRD46 protein (PMID:21219636). In mouse luminal epithelium, Ankrd46 is repressed by miR-451 in a manner implicated in embryo implantation (PMID:25542822). The intrinsic molecular function and biochemical activity of the ANKRD46 protein have not been characterized in the available corpus; all available evidence positions it as a downstream node of miRNA-mediated regulation across cancer and reproductive tissues.

1. 2011 Medium

   Established ANKRD46 as a bona fide direct target of an oncogenic miRNA, defining the first regulatory input into this otherwise uncharacterized gene.

   Evidence Luciferase 3' UTR reporter, Western blot, and LNA-based miR-21 knockdown in breast cancer cells

   PMID:21219636

   Open questions at the time

   • No characterization of ANKRD46 protein function or biochemical activity
   • Whether ANKRD46 mediates downstream phenotypes of miR-21 was not tested
   • No subcellular localization or interaction data
2. 2014 Medium

   Extended ANKRD46 regulation beyond cancer to a developmental context by showing miR-451 represses it in luminal epithelium during embryo implantation.

   Evidence Dual-luciferase reporter assay with in vivo miR-451 loss-of-function (inhibitor/sponge) and qRT-PCR in mouse

   PMID:25542822

   Open questions at the time

   • Mechanistic role of Ankrd46 protein in implantation not defined
   • Downstream effectors of Ankrd46 unknown
   • No demonstration of direct phenotypic rescue by Ankrd46 modulation
3. 2014 Low

   Reinforced miR-21-mediated repression of ANKRD46 in a second cancer type, using ANKRD46 induction as a readout of anti-miR-21 activity.

   Evidence Anti-miR-21 treatment with ANKRD46 expression readout in hepatocellular carcinoma cells

   PMID:25550434

   Open questions at the time

   • ANKRD46 used only as a functional readout, no direct mechanistic experiments on the gene
   • Causal contribution of ANKRD46 to growth inhibition not isolated
4. 2023 Low

   Placed ANKRD46 within the circ_PRDM5/miR-25-3p competing-endogenous-RNA axis in breast cancer, adding a third miRNA regulator.

   Evidence Dual-luciferase reporter, Western blot, proliferation/migration assays, and xenograft in breast cancer

   PMID:37485755

   Open questions at the time

   • Mechanistic role of ANKRD46 protein itself not characterized
   • How ANKRD46 retards tumor progression at the molecular level is unknown
   • Direct binding of miR-25-3p to ANKRD46 versus indirect effects not fully separated
5. 2023 Low

   Associated ANKRD46 expression with the IL6-JAK-STAT3 pathway in fibrotic tissue, hinting at a pathway context but without defining ANKRD46's molecular action.

   Evidence Western blot, qRT-PCR, IHC, flow cytometry, and machine-learning biomarker analysis in keloid/T2DM mouse models

   PMID:41346282

   Open questions at the time

   • Association reported without mechanistic linkage of ANKRD46 to IL6-JAK-STAT3 signaling
   • Whether ANKRD46 acts upstream or downstream of the pathway is undetermined
   • No direct biochemical or interaction data

• The intrinsic molecular function, biochemical activity, subcellular localization, and physical interaction partners of the ANKRD46 protein remain undefined.
• No enzymatic or binding activity assigned
• No localization or complex membership established
• Downstream effectors mediating its phenotypic roles unknown